Flu vaccine only 23 percent effective this season
the ONA take:
In early January, the Centers for Disease Control and Prevention (CDC) issued a report that supports earlier findings, stating that the efficacy of this year's flu vaccine is low.
A CDC analysis of 2, 321 adults and children with acute respiratory illness found that 41% carried the virus, with 96% having influenza A and the remaining 4% influenza B. Based on this, the CDC estimates that this year's vaccine has reduced an individual's chances of a flu-related doctor visit by 23%.
A reason for the low efficacy could be due to the fact that 70% of this season's H3N2 viruses have been categorized as "drift variants"—viruses that are genetically different from the strains used to make this season's vaccine.
Approximately 96% of the individuals found in the CDC test to have the flu had influenza A, which are all H3N2 viruses. Vaccine effectiveness against the H3N2 viruses appeared to be greatest amongst the young, with children and teenagers of age 6 months through 17 years showing 26% effectiveness.
Rates of effectiveness were lower for adults 50 years old or older, at 14%, and lower still for the middle demographic of adults of age 18-49, at 12%. H3N2 viruses result in the higher number of hospitalizations and deaths.
Based on this report, the CDC urges all individuals at high risk for flu-related complications to seek out treatment immediately if influenza type symptoms are experienced. The Cdv still recommends that all individuals 6 months of age or older get vaccinated, as the vaccine still protects some people and could also protect against other viruses that may appear at a later date.
The CDC issued a report that supports earlier findings, stating that the efficacy of this year's flu vaccine is low.
Sign Up for Free e-newsletters
- Triplet Regimen Found Most Effective for Relapsed/Refractory Multiple Myeloma
- Integrating Preoperative Oral Care Into Cancer Treatment Plans
- Current Status and Dilemma of Second-line Treatment in Advanced Pancreatic Cancer: Is There a Silver Lining?
- American Association for Cancer Research Releases Its 2018 Annual Report
- Pulmonary Toxicity Increased in Pediatric Hodgkin Lymphoma Treated With Brentuximab Vedotin
- Benefit of Chemotherapy for Breast Cancer Observed With Midrange Gene Assay Score
- Antioxidant Interaction With Cancer Therapy
- Young Survivors of Breast Cancer Report Sexual Quality of Life Declines After Treatment
- Myeloablative Conditioning Effective in AML Secondary to MDS/MPN Prior to Allogeneic HCT
- Insurance Status Influences Overall Survival in Follicular Lymphoma
- Skin Cancer Screening: Are They Effective?
- Metronidazole, Vancomycin Recommended for C Difficile in Pediatric Oncology, HSCT
- CDC: HPV Vaccination Rates on the Rise Among Adolescents
- High-Dose vs Standard-Dose Flu Vaccine in Elderly Receiving Chemotherapy
- FDA Grants Approval to Novel Treatment for Hairy Cell Leukemia
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|